Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

JNJ Johnson and Johnson

145,02

0,55 (0,38%)

14 Jan 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/30/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert J. Decker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Johnson and Johnson.

Notícias Johnson and Johnson

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Segunda, 13 de Janeiro de 2025 (1 dia atrás) • Edgar (US Regulatory)

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Segunda, 13 de Janeiro de 2025 (2 dias atrás) • GlobeNewswire Inc.

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Segunda, 13 de Janeiro de 2025 (2 dias atrás) • Business Wire

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Quinta, 9 de Janeiro de 2025 (6 dias atrás) • PR Newswire (US)

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Quarta, 8 de Janeiro de 2025 (7 dias atrás) • PR Newswire (US)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Terça, 7 de Janeiro de 2025 (1 semana atrás) • PR Newswire (US)

Johnson & Johnson anuncia dividendos para BDRs com valores e datas confirmados
Sexta, 3 de Janeiro de 2025 (2 semanas atrás) • ADVFN News

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Quinta, 2 de Janeiro de 2025 (2 semanas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 12 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 12 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 12 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Quinta, 12 de Dezembro de 2024 (1 mês atrás) • Business Wire

Mais Notícias de Johnson and Johnson

Índice Bovespa

Brava Energia ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições